276 related articles for article (PubMed ID: 36961477)
1. Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
Stenzinger A; Cuffel B; Paracha N; Vail E; Garcia-Foncillas J; Goodman C; Lassen U; Vassal G; Sullivan SD
Oncologist; 2023 May; 28(5):e242-e253. PubMed ID: 36961477
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States.
Zou D; Ye W; Hess LM; Bhandari NR; Ale-Ali A; Foster J; Quon P; Harris M
J Mol Diagn; 2022 Aug; 24(8):901-914. PubMed ID: 35688357
[TBL] [Abstract][Full Text] [Related]
3. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
4. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
Bestvina CM; Waters D; Morrison L; Emond B; Lafeuille MH; Hilts A; Lefebvre P; He A; Vanderpoel J
J Med Econ; 2024; 27(1):292-303. PubMed ID: 38391239
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.
Loong HH; Shimizu T; Prawira A; Tan AC; Tran B; Day D; Tan DSP; Ting FIL; Chiu JW; Hui M; Wilson MK; Prasongsook N; Koyama T; Reungwetwattana T; Tan TJ; Heong V; Voon PJ; Park S; Tan IB; Chan SL; Tan DSW
ESMO Open; 2023 Aug; 8(4):101586. PubMed ID: 37356359
[TBL] [Abstract][Full Text] [Related]
6. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
7. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Mosele F; Remon J; Mateo J; Westphalen CB; Barlesi F; Lolkema MP; Normanno N; Scarpa A; Robson M; Meric-Bernstam F; Wagle N; Stenzinger A; Bonastre J; Bayle A; Michiels S; Bièche I; Rouleau E; Jezdic S; Douillard JY; Reis-Filho JS; Dienstmann R; André F
Ann Oncol; 2020 Nov; 31(11):1491-1505. PubMed ID: 32853681
[TBL] [Abstract][Full Text] [Related]
9. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.
Vanderpoel J; Stevens AL; Emond B; Lafeuille MH; Hilts A; Lefebvre P; Morrison L
J Med Econ; 2022; 25(1):457-468. PubMed ID: 35289703
[TBL] [Abstract][Full Text] [Related]
10. Implementing Genomic Testing for Lung Cancer Into Routine Clinical Practice - The Welsh Experience.
Cox S; Powell C; Morgan S
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):716-723. PubMed ID: 36088167
[TBL] [Abstract][Full Text] [Related]
11. Value of next generation sequencing (NGS) testing in advanced cancer patients.
Ortendahl JD; Cuyun Carter G; Thakkar SG; Bognar K; Hall DW; Abdou Y
J Med Econ; 2024; 27(1):519-530. PubMed ID: 38466204
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers.
Arriola E; Bernabé R; Campelo RG; Biscuola M; Enguita AB; López-Ríos F; Martínez R; Mezquita L; Palanca S; Pareja MJ; Zugazagoitia J; Arrabal N; García JF; Carcedo D; de Álava E
JCO Precis Oncol; 2023 Mar; 7():e2200546. PubMed ID: 36862967
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study.
Kang DW; Park SK; Yu YL; Lee Y; Lee DH; Kang S
ESMO Open; 2024 Jan; 9(1):102200. PubMed ID: 38194884
[TBL] [Abstract][Full Text] [Related]
14. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.
Nesline MK; Subbiah V; Previs RA; Strickland KC; Ko H; DePietro P; Biorn MD; Cooper M; Wu N; Conroy J; Pabla S; Zhang S; Wallen ZD; Sathyan P; Saini K; Eisenberg M; Caveney B; Severson EA; Ramkissoon S
Oncol Ther; 2024 Mar; ():. PubMed ID: 38502426
[TBL] [Abstract][Full Text] [Related]
16. Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.
Lemmon CA; Zhou J; Hobbs B; Pennell NA
JCO Precis Oncol; 2023 Jan; 7():e2200294. PubMed ID: 36634300
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations.
Choi YJ; Choi JY; Kim JW; Lim AR; Lee Y; Chang WJ; Lee S; Sung JS; Chung HJ; Lee JW; Kang EJ; Kim JS; Lim T; Kim HS; Kim YJ; Ahn MS; Kim YS; Park JH; Lim S; Cho SS; Cho JH; Shin SW; Park KH; Kim YH
Cancer Res Treat; 2022 Jan; 54(1):30-39. PubMed ID: 34015890
[TBL] [Abstract][Full Text] [Related]
18. NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?
Falk AT; Heeke S; Hofman V; Lespinet V; Ribeyre C; Bordone O; Poudenx M; Otto J; Garnier G; Castelnau O; Guigay J; Leroy S; Marquette CH; Hofman P; Ilié M
Expert Rev Anticancer Ther; 2017 Aug; 17(8):681-685. PubMed ID: 28511612
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
[TBL] [Abstract][Full Text] [Related]
20. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
